Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

News | Stents Bioresorbable

February 14, 2024 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced that ...

Home February 14, 2024
Home
News | Stents Bioresorbable

October 30, 2023 — Abbott announced late-breaking data from the LIFE-BTK clinical trial evaluating the Esprit BTK ...

Home October 30, 2023
Home
News | Stents Bioresorbable

September 5, 2023 — New data from the BIOMAG-I first-in-human trial shed light on the vascular healing process following ...

Home September 05, 2023
Home
News | Stents Bioresorbable

March 16, 2023 — Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results of the B ...

Home March 16, 2023
Home
News | Stents Bioresorbable

October 11, 2022 —  Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced that it ...

Home October 11, 2022
Home
News | Stents Bioresorbable

September 28, 2022 —  In the "TCT Innovation" session Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator ...

Home September 28, 2022
Home
News | Stents Bioresorbable

September 27, 2022 —  BIOTRONIK announced the presentation of new full-cohort 2-year BIOSOLVE-IV data. In a poster ...

Home September 27, 2022
Home
News | Stents Bioresorbable

December 16, 2020 — Efemoral Medical announced the first-in-human (FIH) use of the its Efemoral bioresorbable vascular ...

Home December 16, 2020
Home
News | Stents

November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT ...

Home November 24, 2020
Home
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
Videos | Cath Lab

Gregg Stone, M.D., presents the results of the PROSPECT ABSORB Trial in a press conference at the 2020 ranscatheter ...

Home October 17, 2020
Home
Abbott Espirit BTK Bioresorbable stent, or bioresorbable vascular scaffold (BVS) measures 99 microns and is made from poly-L-lactide (PLLA), a semi-crystalline bioresorbable polymer engineered to resist vessel recoil and provide a platform for drug delivery. Abbott Absorb
Feature | Stents Bioresorbable

September 3, 2020 — Abbott today announced the start of the LIFE-BTK clinical trial to evaluate the safety and ...

Home September 03, 2020
Home
The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.
Feature | Stents | Saloni Walimbe

Cardiovascular diseases (CVDs) are among the leading causes of death across the globe. For patients suffering from high ...

Home February 11, 2020
Home
News

November 8, 2019 — The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients with ...

Home November 08, 2019
Home
News | Stents Bioresorbable

November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was taken off the market due ...

Home November 07, 2019
Home
Subscribe Now